Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (220)	2/24/1998 11:47:00 PM
From: Miljenko Zuanic	Respond to of 3559

REGN and PCOP have research collaboration on small molecules cytokines antagonists based on REGN cytokines trap: IL-4, -6, -10. PCOP have chemical library of >3M compounds. Very impressive. So, my statement about broad collaborations means screening PCOP library in REGN assay for Tie1/2-Angio, MUSK, MAP, OXOKIME, ... REGN in early 97 (after BDGF failure) stated in business plan that they will broad efforts in small molecules projects. So, they are holding this information as internal (I do not think that they are developing combinatorial chemistry in-house, does P&G have one=?) or they are behind in business plan. mz [EOM]